Macrophages as novel cellular vehicles for gene therapy

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

Macrophages accumulate in pathological sites, including tumours, atherosclerotic plaques, arthritic joints and sites of infection. This fact led to the concept of introducing ex vivo genetically modified macrophages into a patient, where they would then 'home' to the sites of disease. For this novel and powerful approach to become a reality, the difficulty of efficiently transfecting macrophages and the tendency of transferred macrophages to locate to non-target sites must be overcome. Great progress has been made in the transfection of macrophages using viral vectors, and in the use of stably transfected CD34(+) precursors of monocytes/macrophages, which could allow the bone marrow of patients with genetic disorders to be permanently enhanced with genetically modified cells. Lack of specificity in macrophage homing to diseased sites is proving to be a problem and will most likely need to be circumvented by the use of means such as disease- or site-specific transcriptional targeting to control expression of the therapeutic transgene.

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalExpert Opinion on Biological Therapy
Volume3
Issue number6
DOIs
Publication statusPublished - Sep 2003
Externally publishedYes

Fingerprint

Gene therapy
Macrophages
Genetic Therapy
Inborn Genetic Diseases
Atherosclerotic Plaques
Transgenes
Arthritis
Transfection
Tumors
Monocytes
Bone
Joints
Bone Marrow
Infection

Keywords

  • Animals
  • Genetic Therapy/methods
  • Genetic Vectors
  • Humans
  • Macrophages/physiology
  • Transcriptional Activation/physiology
  • Transfection

Cite this

Macrophages as novel cellular vehicles for gene therapy. / Burke, Bernard.

In: Expert Opinion on Biological Therapy, Vol. 3, No. 6, 09.2003, p. 919-924.

Research output: Contribution to journalReview article

@article{4ab9b96e1f9342f38ca8e775001e725b,
title = "Macrophages as novel cellular vehicles for gene therapy",
abstract = "Macrophages accumulate in pathological sites, including tumours, atherosclerotic plaques, arthritic joints and sites of infection. This fact led to the concept of introducing ex vivo genetically modified macrophages into a patient, where they would then 'home' to the sites of disease. For this novel and powerful approach to become a reality, the difficulty of efficiently transfecting macrophages and the tendency of transferred macrophages to locate to non-target sites must be overcome. Great progress has been made in the transfection of macrophages using viral vectors, and in the use of stably transfected CD34(+) precursors of monocytes/macrophages, which could allow the bone marrow of patients with genetic disorders to be permanently enhanced with genetically modified cells. Lack of specificity in macrophage homing to diseased sites is proving to be a problem and will most likely need to be circumvented by the use of means such as disease- or site-specific transcriptional targeting to control expression of the therapeutic transgene.",
keywords = "Animals, Genetic Therapy/methods, Genetic Vectors, Humans, Macrophages/physiology, Transcriptional Activation/physiology, Transfection",
author = "Bernard Burke",
year = "2003",
month = "9",
doi = "10.1517/14712598.3.6.919",
language = "English",
volume = "3",
pages = "919--924",
journal = "Expert Opinion on Biological Therapy",
issn = "1471-2598",
publisher = "Taylor & Francis",
number = "6",

}

TY - JOUR

T1 - Macrophages as novel cellular vehicles for gene therapy

AU - Burke, Bernard

PY - 2003/9

Y1 - 2003/9

N2 - Macrophages accumulate in pathological sites, including tumours, atherosclerotic plaques, arthritic joints and sites of infection. This fact led to the concept of introducing ex vivo genetically modified macrophages into a patient, where they would then 'home' to the sites of disease. For this novel and powerful approach to become a reality, the difficulty of efficiently transfecting macrophages and the tendency of transferred macrophages to locate to non-target sites must be overcome. Great progress has been made in the transfection of macrophages using viral vectors, and in the use of stably transfected CD34(+) precursors of monocytes/macrophages, which could allow the bone marrow of patients with genetic disorders to be permanently enhanced with genetically modified cells. Lack of specificity in macrophage homing to diseased sites is proving to be a problem and will most likely need to be circumvented by the use of means such as disease- or site-specific transcriptional targeting to control expression of the therapeutic transgene.

AB - Macrophages accumulate in pathological sites, including tumours, atherosclerotic plaques, arthritic joints and sites of infection. This fact led to the concept of introducing ex vivo genetically modified macrophages into a patient, where they would then 'home' to the sites of disease. For this novel and powerful approach to become a reality, the difficulty of efficiently transfecting macrophages and the tendency of transferred macrophages to locate to non-target sites must be overcome. Great progress has been made in the transfection of macrophages using viral vectors, and in the use of stably transfected CD34(+) precursors of monocytes/macrophages, which could allow the bone marrow of patients with genetic disorders to be permanently enhanced with genetically modified cells. Lack of specificity in macrophage homing to diseased sites is proving to be a problem and will most likely need to be circumvented by the use of means such as disease- or site-specific transcriptional targeting to control expression of the therapeutic transgene.

KW - Animals

KW - Genetic Therapy/methods

KW - Genetic Vectors

KW - Humans

KW - Macrophages/physiology

KW - Transcriptional Activation/physiology

KW - Transfection

U2 - 10.1517/14712598.3.6.919

DO - 10.1517/14712598.3.6.919

M3 - Review article

VL - 3

SP - 919

EP - 924

JO - Expert Opinion on Biological Therapy

JF - Expert Opinion on Biological Therapy

SN - 1471-2598

IS - 6

ER -